Cerebellar ataxia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cerebellar ataxia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Ubiquinol and Ascorbic Acid for Patients with Mitochondrial Disorders and Cerebellar Ataxias https://clinicaltrials.eu/trial/study-on-the-effects-of-ubiquinol-and-ascorbic-acid-for-patients-with-mitochondrial-disorders-and-cerebellar-ataxias/ Wed, 29 Apr 2026 15:01:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ubiquinol-and-ascorbic-acid-for-patients-with-mitochondrial-disorders-and-cerebellar-ataxias/ This clinical trial is focused on studying the effects of a treatment for patients with mitochondrial disorders and cerebellar ataxias. These are conditions that affect the energy production in cells and the coordination of movement, respectively. The treatment being tested is a medication called Ubiquinol, which is a form of coenzyme Q10, a substance that helps cells produce energy. The medication is provided as a powder for oral suspension, meaning it is mixed with liquid and taken by mouth.

The purpose of the study is to determine how safe and effective Ubiquinol is for people with these conditions. Participants in the study will take the medication for a period of 18 months. During this time, they will have regular visits to monitor their health and any changes in their condition. The study will look at various aspects such as cognitive function, language skills, quality of life, and the severity of symptoms. Additionally, the study will assess the levels of coenzyme Q10 in the blood to understand how the body processes the medication.

Throughout the study, participants will be asked about any side effects they experience. The study aims to provide valuable information on whether Ubiquinol can be a beneficial treatment option for those with mitochondrial disorders and cerebellar ataxias. This research could lead to improved management of these conditions and enhance the quality of life for those affected.

]]>